HIGHLIGHTS
- who: Ruben Mesa from the (UNIVERSITY) have published the paper: Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis, in the Journal: (JOURNAL) of 22/07/2022
- what: Both studies were designed to provide 24-week comparative data while the survival outcomes might be considered descriptive for patients treated with extended MMB as most control arm patients crossed over to MMB at a relatively early timepoint relative to the median survival follow-up of more than three years.
- future: High MMB dose intensity was . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.